Rabin Medical Center Reports Findings in Heart Attack (Comparative Analysis of First-Line Antihypertensive Treatment Classes): Heart Disorders and Diseases – Heart Attack

2024 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Middle East Daily -- New research on Heart Disorders and Diseases - Heart Attack is the subject of a report. According to news reporting out of Petah-Tikva, Israel, by NewsRx editors, research stated, “The best first-line monotherapy for hypertension remains uncertain, as current guidelines suggest that thiazides, angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), and calcium channel blockers (CCB) are appropriate in the absence of specific comorbidities. We aimed to compare the outcomes of first-line antihypertensive classes in a real-life setting with a long follow-up period.”

Our news journalists obtained a quote from the research from Rabin Medical Center, “This nationwide retrospective new-user cohort study included patients insured by the largest health maintenance organization in Israel. We included patients with a new diagnosis of hypertension between 2008 and 2021 who initiated treatment with a single first-line drug for hypertension. Outcomes were assessed with and without propensity score matching for confounding factors. The primary composite outcome was the first occurrence of myocardial infarction (MI), acute coronary syndrome (ACS), stroke, or heart failure (HF). A total of 97,639 patients initiated antihypertensive treatment with a single drug as first-line therapy. The most commonly prescribed class was ACEi/ARB (66,717, 68.3%), followed by CCBs (15,922, 16.3%), beta-blockers (BBs, 12,869, 13.2%), and thiazides (2,131, 2.2%). For the primary outcome, the hazard ratios (HRs) for BBs, CCBs, and ACEi/ARBs were 1.44 (95% CI 1.25 - 1.66), 1.10 (95% CI 0.96 - 1.27), and 1.13 (95% CI 0.99 - 1.29), respectively, when compared to thiazides.”

According to the news editors, the research concluded: “When initiating pharmacotherapy for hypertension with a single drug, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers were associated with similar risk of MI, ACS, stroke, or HF when compared to thiazides, while beta-blockers were associated with increased risk.”

This research has been peer-reviewed.

For more information on this research see: Comparative Analysis of First-Line Antihypertensive Treatment Classes. The American Journal of Medicine, 2024. The American Journal of Medicine can be contacted at: Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA.

Our news journalists report that additional information may be obtained by contacting Ran Abuhasira, Dept. of Internal Medicine B, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel. Additional authors for this research include Nitzan Burrack, Adi Turjeman, Yonatan Shneor Patt, Leonard Leibovici and Alon Grossman.

Publisher contact information for the The American Journal of Medicine is: Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)